# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Arthur He maintains HOOKIPA Pharma (NASDAQ:HOOK) with a Buy and raises the price target from...
Encouraging clinical activity with observed deepening of responses in 35 evaluable first line head and neck patients treated wi...
RBC Capital analyst Brian Abrahams reiterates HOOKIPA Pharma (NASDAQ:HOOK) with a Outperform and maintains $5 price target.
HOOKIPA Pharma (NASDAQ:HOOK) reported quarterly earnings of $0.11 per share which beat the analyst consensus estimate of $(0.10...